经皮微波消融治疗鼻咽癌局限肝转移的疗效分析

背景与目的：局限性肝转移瘤由于数目、大小可控，局部微创治疗可以有效提高患者的生存期，微波消融已经成为肝转移瘤的重要治疗手段。该研究旨在探讨经皮肝穿刺微波消融治疗局限性鼻咽癌肝转移瘤的应用价值。方法：收集湖南省肿瘤医院自2011年9月—2014年10月共26例晚期放化疗失败的鼻咽癌肝脏转移患者的临床资料。患者肿瘤病灶数目小于等于3个，直径小于等于5 cm，且无其他远处转移病灶。在B超引导下行经皮肝穿刺微波消融治疗，26例患者共完成43次消融治疗，术后1个月复查肝功能、增强CT或者MRI，在mRECIST标准评价肿瘤治疗疗效。观察患者术后并发症，统计患者无疾病进展时间(progression-free survival，PFS)及总生存期(overall survival，OS)。结果：26例患者共53个病灶，其中完全消融(complete ablation，CA)20例(20/26，77.0%)，部分消融(part ablation，PA)3例(3/26，11.5%)，整体有效率(CA+PA)为88.5%，无严重并发症出现，26例患者0.5、1和2年生存率分别为96.1%、65.3%和23.0%，PFS为11.4个月，中位生存期(median survival time，MST)为17.8个月，OS为23.7个月。结论：经皮肝穿刺微波消融治疗局限性鼻咽癌肝转移瘤是微创、安全、有效的治疗方法。

The efficacy of percutaneous microwave ablation for limited liver metastases of nasopharyngeal ;carcinoma

Background and purpose:Since the number and tumor size of localized liver metastases can be controlled, local minimally invasive treatment can improve the survival of patients. Hence, microwave ablation has become an important treatment method for liver metastases. This study was to investigate the value of percutaneous microwave ablation in the treatment of tumor metastases. Methods: From Sep. 2011 to Oct. 2014, 26 advanced nasopharyngeal carcinoma patients with post-chemotherapy consolidation, liver metastases were collected. All the patients with the number of tumor lesions less than 3, diameter less than 5 cm, no other distant metastases was excluded. The ultrasound-guided percutaneous microwave ablation was used for 26 patients. Finally, 43 ablations were completed followed by liver function test, enhanced CT and MRI diagnosis 1 month later. mRECIST criteria was used to evaluate the effcacy of cancer treatment. Progression-free survival (PFS) and overall survival (OS) were calculated. Results:Twenty-six cases of a total of 53 lesions, including complete ablation (CA) 20 patients (20/26, 77.0%), partial ablation (PA) 3 patients (3/26,11.5%). The overall effciency was 88.5%(CA+PA) with no serious complications. 6 months, 1-, 2-year survival rates of 26 patients were 96.1%, 65.3%and 23.0%. PFS was 11.4 months. The median survival time (MST) was 11.9 months, while OS was 23.7 months. Conclusion:Percutaneous microwave ablation for limited liver metastases of nasopharyngeal carcinoma is a minimally invasive, safe and effective treatment method.